Patents by Inventor Steven D. Rosen
Steven D. Rosen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120328632Abstract: This invention relates to the inhibition of intercellular adhesion mediated by L-selectin by administering a newly identified L-selectin ligand, CD34. More particularly, the invention concerns a method for inhibiting leukocyte adhesion to endothelial cells by administering an effective amount of an isolated, purified CD34 polypeptide or an antibody capable of binding native CD34.Type: ApplicationFiled: December 21, 2011Publication date: December 27, 2012Applicant: Genentech, Inc.Inventors: Laurence A. Lasky, Susanne Baumhueter, Steven D. Rosen, Mark S. Singer
-
Patent number: 8216580Abstract: Novel sulfatases and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including various diagnostic and therapeutic agent screening applications. Also provided are methods of inhibiting tumor-induced angiogenesis and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of a subject sulfatase.Type: GrantFiled: June 27, 2008Date of Patent: July 10, 2012Assignee: The Regents of the University of CaliforniaInventors: Roman Nawroth, Steven D. Rosen
-
Publication number: 20080241143Abstract: This invention relates to the inhibition of intercellular adhesion mediated by L-selectin by administering a newly identified L-selectin ligand, CD34. More particularly, the invention concerns a method for inhibiting leukocyte adhesion to endothelial cells by administering an effective amount of an isolated, purified CD34 polypeptide or an antibody capable of binding native CD34.Type: ApplicationFiled: September 26, 2007Publication date: October 2, 2008Inventors: Laurence A. Lasky, Susanne Baumhueter, Steven D. Rosen, Mark S. Singer
-
Patent number: 6967093Abstract: A novel human glycosylsulfotransferase expressed in high endothelial cells (GST-3) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting selectin mediated binding events and methods of treating disease conditions associated therewith.Type: GrantFiled: March 22, 2001Date of Patent: November 22, 2005Assignees: The Regents of the University of California, Syntex (U.S.A) LLCInventors: Annette Bistrup, Steven D. Rosen, Stefan Hemmerich
-
Patent number: 6933142Abstract: Mammalian glycosylsulfotransferases expressed in high endothelial cells (HEC-GLCNAC6ST) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting selectin mediated binding events and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of at least one of HEC-GLCNAC6ST or KSGal6ST, or homologues thereof.Type: GrantFiled: August 23, 2000Date of Patent: August 23, 2005Assignees: The Regents of the University of California, Syntex (USA), LLCInventors: Annette Bistrup, Steven D. Rosen, Stefan Hemmerich
-
Patent number: 6852518Abstract: Novel glycosylsulfotransferases (GST-4?, GST-4?, and GST-6) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including various diagnostic and therapeutic agent screening applications. Also provided are methods of inhibiting selectin mediated binding events and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of at least one of GST-4?, GST-4?, and GST-6.Type: GrantFiled: June 13, 2000Date of Patent: February 8, 2005Assignees: The Regents of the University of California, Syntex (U.S.A.) LLCInventors: Steven D. Rosen, Jin Kyu Lee, Stefan Hemmerich
-
Patent number: 6844175Abstract: A novel human glycosylsulfotransferase expressed in high endothelial cells (GST-3) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications.Type: GrantFiled: November 8, 2001Date of Patent: January 18, 2005Assignees: The Regents of the University of the California, Syntex (U.S.A.) INCInventors: Annette Bistrup, Steven D. Rosen, Kirsten Tangemann, Stefan Hemmerich
-
Publication number: 20040185546Abstract: Novel glycosylsulfotransferases (GST-4&agr;, GST-4&bgr;, and GST-6) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including various diagnostic and therapeutic agent screening applications. Also provided are methods of inhibiting selectin mediated binding events and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of at least one of GST-4&agr;, GST-4&bgr;, and GST-6.Type: ApplicationFiled: October 29, 2003Publication date: September 23, 2004Inventors: Steven D. Rosen, Jin Kyu Lee, Stefan Hemmerich
-
Publication number: 20040141966Abstract: This invention relates to the inhibition of intercellular adhesion mediated by L-selectin by administering a newly identified L-selectin ligand, CD34. More particularly, the invention concerns a method for inhibiting leukocyte adhesion to endothelial cells by administering an effective amount of an isolated, purified CD34 polypeptide or an antibody capable of binding native CD34.Type: ApplicationFiled: January 15, 2003Publication date: July 22, 2004Applicant: Genentech, Inc.; The Regents of the University of CaliforniaInventors: Laurence A. Lasky, Susanne Baumhueter, Steven D. Rosen, Mark S. Singer
-
Publication number: 20020164748Abstract: A novel human glycosylsulfotransferase expressed in high endothelial cells (GST-3) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting selectin mediated binding events and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of at least one of GST-3 or KSGal6ST, or homologues thereof.Type: ApplicationFiled: November 8, 2001Publication date: November 7, 2002Inventors: Annette Bistrup, Steven D. Rosen, Kirsten Tangemann, Stefan Hemmerich
-
Patent number: 6395882Abstract: Podocalyxin like proteins (e.g. PCLP and PCLP-2) having selectin ligand activity are provided. Also provided are nucleic acid compositions encoding novel PCLP-2 proteins. The subject polypeptide and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications, as well as in treatment therapies for disease conditions associated with podocalyxin like protein activity. In particular, methods of treating diseases associated with podocalyxin like protein selectin binding activity and/or chemokine presenting activity are provided, where such diseases include inflammation and the like.Type: GrantFiled: February 3, 1999Date of Patent: May 28, 2002Assignee: The Regents of the University of CaliforniaInventors: Steven D. Rosen, Christopher M. Sassetti
-
Patent number: 6380371Abstract: Nucleic acid compositions encoding novel endoglycan proteins, as well as the novel endoglycan proteins, are provided. Also provided are methods of producing the subject nucleic acid and protein compositions. The subject polypeptide and nucleic acid compositions find use in a variety of applications, including diagnostic and therapeutic agent screening applications, as well as in treatment therapies for disease conditions associated with endoglycan activity. In particular, methods of treating diseases associated with endoglycan selectin binding activity and/or chemokine presenting activity are provided, where such diseases include inflammation and the like.Type: GrantFiled: September 13, 1999Date of Patent: April 30, 2002Assignee: The Regents of the University of CaliforniaInventors: Christopher M. Sassetti, Steven D. Rosen
-
Patent number: 6365365Abstract: A novel human glycosylsulfotransferase expressed in high endothelial cells (GST-3) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting selectin mediated binding events and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of at least one of GST-3 or KSGal6ST, or homologues thereof.Type: GrantFiled: November 12, 1998Date of Patent: April 2, 2002Assignee: The Regents of the University of CaliforniaInventors: Annette Bistrup, Steven D. Rosen, Kirsten Tangemann, Stefan Hemmerich
-
Publication number: 20020025923Abstract: Podocalyxin like proteins (e.g. PCLP and PCLP-2) having selectin ligand activity are provided. Also provided are nucleic acid compositions encoding novel PCLP-2 proteins. The subject polypeptide and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications, as well as in treatment therapies for disease conditions associated with podocalyxin like protein activity. In particular, methods of treating diseases associated with podocalyxin like protein selectin binding activity and/or chemokine presenting activity are provided, where such diseases include inflammation and the like.Type: ApplicationFiled: May 18, 2001Publication date: February 28, 2002Inventors: Steven D. Rosen, Christopher M. Sassetti
-
Publication number: 20010051370Abstract: A novel human glycosylsulfotransferase expressed in high endothelial cells (GST-3) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting selectin mediated binding events and methods of treating disease conditions associated therewith.Type: ApplicationFiled: March 22, 2001Publication date: December 13, 2001Inventors: Annette Bistrup, Steven D. Rosen, Stefan Hemmerich
-
Patent number: 6265192Abstract: A novel human glycosylsulfotransferase expressed in high endothelial cells (GST-3) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid compositions find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting selectin mediated binding events and methods of treating disease conditions associated therewith.Type: GrantFiled: March 20, 1998Date of Patent: July 24, 2001Assignees: The Regents of the University of California, Syntex, Inc.,Inventors: Annette Bistrup, Steven D. Rosen, Stefan Hemmerich
-
Patent number: 5977080Abstract: Sulfated disaccharides characterized by the ability to inhibit the binding of selectin to its physiologically-relevant ligand are disclosed. Included are efficient and inexpensive methods for producing the sulfated disaccharides, and methods for their therapeutic use and in in vivo and in vitro assays.Type: GrantFiled: January 8, 1998Date of Patent: November 2, 1999Assignee: The Regents Of The University Of CaliforniaInventors: Steven D. Rosen, Carolyn Bertozzi
-
Patent number: 5972625Abstract: The present invention provides novel assays for determining the ability of a test compound to inhibit intercellular adhesion mediated by a selectin receptor, such as the LHR. The assay involves coating a surface of a solid substrate with an antibody which specifically binds a selectin ligand. Preferred are antibodies against GlyCAM-1 which is a natural biological ligand for L-Selectin and also binds to P-Selectin and E-Selectin. A compound such as GlyCAM-1 is then bound to the antibodies. The test compound mixture putatively containing a selectin ligand is then brought into contact with a chimeric molecule. The test mixture might include any compound which might block or hinder binding between a selectin receptor and the ligand bound to the antibody.Type: GrantFiled: July 2, 1997Date of Patent: October 26, 1999Assignee: The Regents of the University of CaliforniaInventors: Steven D. Rosen, Mark Singer, Yasuyuki Imai
-
Patent number: 5925349Abstract: Compositions are administered to a patient (preferably by injection and locally) to treat a variety of conditions including inflammation associated with trauma and with certain aspects of diseases such as rheumatoid arthritis, psoriasis, insulin-dependent diabetes, cutaneous lymphomas, duodenal ulcer, chronic proctitis, lymphocytic thyroiditis, hemorphagic shock, reperfusion injury during transplantation and multiple sclerosis. The compositions are pharmaceutically acceptable injectable formulations which include an active component in a pharmaceutically acceptable carrier. The active component is a chlorate or selenate which inhibits the natural biochemical sulfation process and/or a sulfatase enzyme which removes a sulfate from a specific position of a saccharide molecule which makes up a part of a natural ligand for L-selectin. Removal of the sulfate from the ligand hinders the ability of the ligand to bind to its natural receptor (i.e.Type: GrantFiled: August 19, 1997Date of Patent: July 20, 1999Assignee: The Regents Of The University Of CaliforniaInventors: Steven D. Rosen, Stefan Hemmerich, Yasuyuki Imai
-
Patent number: 5840844Abstract: DNA isolates coding for the lymphocyte homing receptor and methods of obtaining such DNA are provided, together with expression systems for recombinant production of the lymphocyte homing receptor useful in therapeutic or diagnostic compositions.Type: GrantFiled: August 10, 1995Date of Patent: November 24, 1998Assignee: Genentech, Inc. University of CaliforniaInventors: Laurence A. Lasky, Steven D. Rosen, Scott E. Stachel, Mark S. Singer